April 28, 2021

Vesalio’s NeVa VS Studied in VITAL Clinical Trial to Support FDA Clearance

April 28, 2021—Vesalio announced the completion of enrollment in the VITAL clinical trial evaluating the company’s NeVa VS in the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

The study, conducted under an investigational device exemption from the FDA, is intended to support the device’s clearance for the United States neurovascular market.

Vesalio’s NeVa platform was designed to achieve first-pass recanalization in acute ischemic stroke by removing all types of neurovascular clots from patient anatomy, stated the company.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

April 28, 2021

Vesalio’s NeVa VS Studied in VITAL Clinical Trial to Support FDA Clearance

Current Issue

Keep In Touch